Online inquiry

IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12413MR)

This product GTTS-WQ12413MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Crohn's disease (CD), Psoriasis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12413MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14250MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ11225MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ3021MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ14866MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ9658MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ16011MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ5920MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ10497MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-2951742
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW